Evolent Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Evolent Health, Inc. on September 13, 2017. The filing addresses corporate governance changes, specifically the election of a new director and an increase in the size of the Board of Directors to comply with New York Stock Exchange (NYSE) regulations.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on governance matters and contains no financial performance data.
Material Changes
- Board Election: Dr. Bridget Duffy was elected as a Class II director and appointed to the Nominating and Governance Committee.
- Board Size: The Board size was increased from 10 to 11 members.
- Independence Status: Following Dr. Duffy's election, the Board now consists of a majority of independent directors, satisfying NYSE requirements that were due by October 3, 2017.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of business risks. It notes that Dr. Duffy is considered an independent director under NYSE standards and that there are no undisclosed transactions involving her or her immediate family. Dr. Duffy will receive standard director indemnification and compensation arrangements applicable to non-employee directors.
Key Facts for Investor Verification
- Dr. Bridget Duffy's background as former CEO of ExperiaHealth and Chief Medical Officer of Vocera.
- Confirmation that the Board now meets the NYSE requirement for a majority of independent directors.
- The effective date of the Board size increase (September 13, 2017).
- Verification that all standing committees (Audit, Compensation, Nominating and Governance) remain fully independent.